Revised. Amendments from Version 1
==================================

We have added some important limitations into the new version, according to the three reviewers.

Correspondence
==============

The genetic basis of ischemic vascular disease such as coronary artery disease is actively being explored. Most studies have focused on susceptibility factors contributing to an increased risk ^[@ref-1]^, while only a few studies have identified protective variants conferring reduced risk ^[@ref-2]^. Recently, the TG and HDL Working Group and Jørgensen *et al.* reported that loss-of-function mutations in *APOC3* are associated with decreased triglyceride levels and a reduced risk of ischemic vascular disease in individuals of European and African ancestry ^[@ref-3],\ [@ref-4]^. Approximately 1 in 150 individuals were heterozygous carriers of at least one of the four mutations: R19X, A43T, IVS2+1G→A, and IVS3+1G→T. Heterozygous carriers for these mutations had a significantly lower incidence of ischemic vascular disease as compared to non-carriers (hazard ratio = 0.59). Triglyceride and circulating *APOC3* levels in the carriers were only 61% and 54% of those in non-carriers, respectively. These critical findings prompted us to undertake a replication study in China, where over one million people are affected by cardiovascular diseases each year ( <http://www.nhfpc.gov.cn/>).

A total of 4470 unrelated Chinese participants were enrolled, including 1488 healthy controls, 1050 patients with ischemic stroke, 628 patients with coronary artery disease, and 1304 patients with venous thrombosis, which could also be exacerbated by effects on the coagulation system resulting from elevated triglyceride levels. The 1488 healthy controls and 1050 patients with ischemic stroke were described in a previous study ^[@ref-5]^. Briefly, healthy individuals did not present any relevant medical history or family history of ischemic vascular disease. Ischemic stroke was confirmed by brain computed tomography (CT) and/or brain magnetic resonance imaging (MRI). The 1304 patients with venous thrombosis were described previously ^[@ref-6]^. Thrombosis was confirmed by objective investigations such as color Doppler ultrasonography and/or CT angiography. Patients with coronary artery disease were enrolled in our hospital from September 2013 to March 2014. Coronary artery disease was validated by angiographic evidence of at least one segment of a major coronary with over 50% organic stenosis. The characteristics of the 628 patients with coronary artery disease are summarized in [Table 1](#T1){ref-type="table"}. Written informed consent was obtained from all participants, and the study was approved by the Ethics Committee of Union Hospital affiliated with Huazhong University of Science and Technology (Approval number 2013-03-0052).

###### Characteristics of the 628 patients with coronary artery disease.

  Characteristic               Number               Percentage
  ---------------------------- -------------------- ------------
  Onset age (yr, mean)         61.6 ± 10.8          
       \<40                    11                   1.7%
       ≥40 and \<60            256                  40.8%
       ≥60                     361                  57.5%
  Sex                                               
       male                    408                  65.0%
       female                  220                  35.0%
  Coronary artery disease                           
       angina pectoris         422                  67.2%
       myocardial infarction   206                  32.8%
  Family history                                    
       yes                     32                   5.1%
       no                      596                  94.9%
  Current smoker                                    
       yes                     157                  25.0%
       no                      471                  75.0%
  Drinking                                          
       yes                     79                   12.6%
       no                      549                  87.4%
  Hypertension                                      
       yes                     425                  67.7%
       no                      203                  32.3%
  Type 2 diabetes                                   
       yes                     175                  27.9%
       no                      453                  72.1%
  Fasting serum lipid levels                        
       TC                      3.97 ± 0.99 mmol/L   
       TG                      1.55 ± 1.05 mmol/L   
       HDL-C                   1.19 ± 0.29 mmol/L   
       LDL-C                   2.07 ± 0.76 mmol/L   

TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

The diagnosis of myocardial infarction was based on typical chest pain with a duration over 30 min, on electrocardiographic patterns, and on increased creatine kinase MB isoenzyme and troponin I levels. Hypertension is defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Type 2 diabetes were clarified using the 1999 WHO criteria, including fasting plasma glucose ≥ 7.0 mmol/L, 2-hour oral glucose tolerance test plasma glucose ≥ 11.1 mmol/L or ongoing therapy for diabetes.

Blood samples were collected into a vacutainer tube containing 0.105 mol/L trisodium citrate and were then centrifuged at 2000 g for 15 minutes. Genomic DNA was isolated using a salt precipitation method and was then used for sequencing. The four exons and the flanking intronic regions of *APOC3* were amplified by PCR and then sequenced on an Applied Biosystems ABI 3730 Genetic Analyzer, as previously described ^[@ref-3]^. The oligonucleotide pairs and annealing temperatures employed in PCR and sequencing are shown in [Table 2](#T2){ref-type="table"}. In this study, we identified only synonymous and intronic variants, with no functional consequences, and similar genotype distributions across the groups ( [Table 3](#T3){ref-type="table"}). None of the loss-of-function mutations reported in European and African individuals were observed in the current cohort. Therefore, the genetic background of ischemic vascular disease is highly variable among different ethnic groups, and *APOC3* may not be an ideal predictor of risk of ischemic vascular disease in the Chinese population.

###### Primers and annealing temperatures for PCR and sequencing.

  -------------------------------------------------------------------------------------
  Exon      Forward primer (5\'-3\')   Reverse primer (5\'-3\')   AT (ºC)   Product\
                                                                            size (bp)
  --------- -------------------------- -------------------------- --------- -----------
  1         GCCTTTACTCCAAACACCCC       AGTGCTTCTCCAGGCTTGCT       58        602

  2 and 3   CCTTCTGAGAGCCCGTATTAGC     CCGCAGCAGCCTGACAAA         58        646

  4         GGGGCATAAACATCTGAGGT       CTACCAGAAGGTGGATAGAGC      58        693
  -------------------------------------------------------------------------------------

AT, annealing temperature. The accession number of *APOC3* reference sequence in GenBank is NG_008949.1.

###### *APOC3* variants identified in the 4470 Chinese participants.

  ---------------------------------------------------------------------------------------------------------------------------
  Variables                  dbSNP ID      Control group\   Ischemic stroke\   Coronary heart disease\   Venous thrombosis\
                                           n = 1488         n = 1050           n = 628                   n = 1304
  -------------------------- ------------- ---------------- ------------------ ------------------------- --------------------
  Age (yr, mean)                           61.2 ± 12.8      62.2 ± 12.3        61.6 ± 10.8               51.7 ± 13.8

  Male, n (%)                              978 (65.7%)      691 (65.8%)        408 (65.0%)               638 (48.9%)

  Variants, n (%) ^b^                                                                                    

      c.10C\>A (p.Arg4=)     novel                                                                       

          CC                               1485 (99.8%)     1048 (99.8%)       627 (99.8%)               1301 (99.8%)

          CA                               3 (0.2%)         2 (0.2%)           1 (0.2%)                  3 (0.2%)

          P value                                           0.95               0.84                      0.87

      c.99G\>A (p.Gln33=)    rs200557528                                                                 

          GG                               1481 (99.5%)     1046 (99.6%)       625 (99.5%)               1296 (99.4%)

          GA                               7 (0.5%)         4 (0.4%)           3 (0.5%)                  8 (0.6%)

          P value                                           0.73               0.98                      0.61

      c.102T\>C (p.Gly34=)   rs4520                                                                      

          TT                               655 (44.0%)      456 (43.4%)        278 (44.3%)               582 (44.6%)

          TC                               641 (43.1%)      449 (42.8%)        272 (43.3%)               566 (43.4%)

          CC                               192 (12.9%)      145 (13.8%)        78 (12.4%)                156 (12.0%)

          P value                                           0.80               0.95                      0.75

      c.179+57G\>A           rs2070667                                                                   

          GG                               1098 (73.8%)     776 (73.9%)        454 (72.3%)               967 (74.2%)

          GA                               329 (22.1%)      235 (22.4%)        148 (23.6%)               286 (21.9%)

          AA                               61 (4.1%)        39 (3.7%)          26 (4.1%)                 51 (3.9%)

          P value                                           0.88               0.76                      0.96

      c.240G\>A (p.Lys80=)   novel                                                                       

          GG                               1483 (99.7%)     1047 (99.7%)       626 (99.7%)               1301 (99.8%)

          GA                               5 (0.3%)         3 (0.3%)           2 (0.3%)                  3 (0.2%)

          P value                                           0.82               0.95                      0.60

      c.\*40G\>C             rs5128                                                                      

          GG                               763 (51.3%)      535 (51.0%)        328 (52.2%)               665 (51.0%)

          GC                               562 (37.8%)      394 (37.5%)        240 (38.2%)               494 (37.9%)

          CC                               163 (10.9%)      121 (11.5%)        60 (9.6%)                 145 (11.1%)

          P value                                           0.90               0.64                      0.98

      c.\*71G\>T             rs4225                                                                      

          GG                               1006 (67.6%)     703 (66.9%)        416 (66.2%)               880 (67.5%)

          GT                               414 (27.8%)      304 (29.0%)        180 (28.7%)               368 (28.2%)

          TT                               68 (4.6%)        43 (4.1%)          32 (5.1%)                 56 (4.3%)

          P value                                           0.73               0.79                      0.92
  ---------------------------------------------------------------------------------------------------------------------------

dbSNP, single nucleotide polymorphism database of the National Center for Biotechnology Information ( <http://www.ncbi.nlm.nih.gov/projects/SNP>).

Comparisons between the controls and each case group were assessed with the use of the chi-square test. A two tailed P\<0.05 was considered significant.

However, there are some limitations in this study. First, we only analyzed the coding sequence, as in the studies carried out in European and African individuals. Potential effects from large deletions and mutations in regulatory regions of the gene cannot be excluded. Previous studies have revealed two promoter polymorphisms (T-455C and C-482T) that affect the expression of *APOC3.* However, their relationship with coronary artery disease was not observed in a Han Chinese population ^[@ref-7]^. Second, the consequences of the synonymous mutations and the intronic mutations identified here were only predicted by an on-line bioinformatics tool ( <http://www.fruitfly.org/seq_tools/splice.html>). Third, the triglyceride levels were not available for the patients with venous thrombosis. Thus, the triglyceride levels according to the genotypes were not further analyzed. Nevertheless, considering the relatively large sample size, we suggest that functional variants in *APOC3* could be very rare in China. Further studies are warranted to understand the genetic basis governing triglyceride levels and conferring protective effects on ischemic vascular disease in the Chinese population.

Consent
=======

Written informed consent to publish these data has been obtained by each participant.
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Authors addressed the main concerns. No further comments.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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The authors performed a confirmatory study for the recently reported protective effects of loss-of-function mutations in *APOC3* in the Chinese population. Not a single loss-of-function mutation was identified in exons and exon-intron junctions of *APOC3* in a total of 4470 study subjects. The authors concluded that *APOC3* is not a good predictor of risk of ischemic vascular disease in the Chinese population.

This is a worthwhile study and the information, although negative, is certainly useful. However, based on the data reported in the paper, it is premature to conclude that functional variants in *APOC3* are very rare and/or not related to ischemic vascular disease in the Chinese population. The data merely conclude that detrimental mutations are very rare in the sequenced regions of *APOC3* gene in the Chinese population. Potential effects from large deletions of the gene and mutations in regulatory regions of the gene cannot be excluded. In fact, there have been reports of promoter polymorphisms that affect the expression of *APOC3* (ref. 28-31 in Jørgensen et. al). Unless additional, more comprehensive mutational studies are performed in the cohort, conclusions should be modified to reflect the limitations of the current study.

There have been examples of synonymous mutations that affect the translation of mRNA and therefore affect the protein level. Also, intronic mutations distant from splice sites could affect splicing. Authors should clearly state reasons why they believe that the variants identified in the study have no functional consequences.

References should be added to the end of the second sentence of the paper (while only "a" few studies have identified protective variants conferring reduced risk).

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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Two very recent landmark large-scale studies show that loss-of-function mutations in APOC3 are associated with lower levels of plasma triglycerides, and carriers of these mutations have a reduced risk of coronary heart disease in European and African individuals. Tang *et al*. performed a timely replication study in 4,470 Chinese individuals. Unexpectedly, no loss-of-function mutations identified in the European and African populations were found in the Chinese population. This important study not only highlights the difference in genetic susceptibility to cardiovascular disease in different ethnic populations, but also suggests that APOC3 variants are not applicable to the Chinese population to predict risk for ischemic vascular disease.

APOC3 may still be an important regulator of lipid metabolism in Chinese, and novel variants of this gene remain to be identified in this ethnic population. Consequently, the authors need to change their conclusion from "Therefore, *APOC3* may not be an ideal predictor for risk of ischemic vascular disease in the Chinese population" to "Therefore, *APOC3* variants identified in the European and African population may not be an ideal predictor for risk of ischemic vascular disease in the Chinese population".

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Despite being a negative study, the information in this article is valuable. It describes a study that found no relevant mutation in *APOC3* among a large number of Chinese subjects (4470), including 1488 healthy controls, 1050 patients with ischemic stroke, 628 patients with coronary artery disease, and 1304 patients with venous thrombosis. Actually, no one with the loss-of-function mutations reported in European and African individuals was identified in this study. Only synonymous and intronic variants were discovered. The authors indicated that these variants have no functional consequences, but no data are shown. At the least the TG levels according to the genotype might be shown in table 2.

The authors must indicate that other genetic defects, such a gross deletions or regulatory mutations not identified by sequencing methods or by analysis of exons, may cause a loss-of-function of *APOC3* and might be associated with decreased triglyceride levels and a reduced risk of ischemic vascular disease. Actually, selection of subjects with decreased triglyceride levels and a deeper analysis of this gene might be a better strategy to identify these genetic variants potentially involved in TG levels and risk of ischemic vascular disease. Accordingly, I think the authors might change the title of the article.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

[^1]: \*Equal contribution

[^2]: YH and LT chose the article for correspondence and evaluated the data in the manuscript. LT, ZPC, QYW, WZ, HL, YYW, and BH performed experiments. LT and ZPC wrote the manuscript. YH supervised the process and critically edited the manuscript.

[^3]: **Competing interests:**No competing interests were disclosed.
